menu
    • menu

    Company profile for Scorpion Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Scorpion Therapeutics, we are working to expand the reach of precision medicine to more people with cancer, including cancers that are untreatable or treatment-resistant today. We are moving with equal parts urgency and rigor to change the status quo, drawing on our team’s expertise and drive to accelerate our impact on patients. Our team is comprised of renowned experts in cancer biology, targeted oncology, and drug deve...
    At Scorpion Therapeutics, we are working to expand the reach of precision medicine to more people with cancer, including cancers that are untreatable or treatment-resistant today. We are moving with equal parts urgency and rigor to change the status quo, drawing on our team’s expertise and drive to accelerate our impact on patients. Our team is comprised of renowned experts in cancer biology, targeted oncology, and drug development – pioneers in cataloging and understanding the genomic events and cellular mechanisms that give rise to cancer; identifying and characterizing the molecular subtypes of disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Scorpion TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    888 Boylston Street Suite 1111 Boston, MA, 02199
    Telephone
    Telephone
    212-841-1015
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.scorpiontx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Antares Therapeutics Launches with $177 Million for Precision Med
    Antares Therapeutics Launches with $177 Million for Precision Med

    10 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250610961759/en/Antares-Therapeutics-Launches-with-%24177-Million-to-Develop-First-in-Class-Precision-Medicines-for-Cancer-and-Other-Serious-Diseases

    BUSINESSWIRE
    10 Jun 2025
    Share Share
    Eli Lilly to buy Scorpion cancer therapy for up to $2.5 billion
    Eli Lilly to buy Scorpion cancer therapy for up to $2.5 billion

    14 Jan 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-buy-cancer-drug-developer-scorpion-therapeutics-25-bln-2025-01-13/

    REUTERS
    14 Jan 2025
    Share Share
    Scorpion Updates On Mutant-Selective PI3K? Inhibitor STX-478
    Scorpion Updates On Mutant-Selective PI3K? Inhibitor STX-478

    10 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241210303352/en

    BUSINESSWIRE
    10 Dec 2024
    Share Share
    Pierre And Scorpion Dose First Patient In PFL-241 Trial Lung Cancer
    Pierre And Scorpion Dose First Patient In PFL-241 Trial Lung Cancer

    08 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241008250275/en

    BUSINESSWIRE
    08 Oct 2024
    Share Share
    Pierre Fabre, Scorpion Start Phase I/II Oncology Trial
    Pierre Fabre, Scorpion Start Phase I/II Oncology Trial

    07 Oct 2024

    // PRESS RELEASE

    https://www.pierre-fabre.com/en/press_release/pierre-fabre-scorpion-therapeutics-announce-new-phase-iii-clinical-trial-for-an

    PRESS RELEASE
    07 Oct 2024
    Share Share
    Scorpion Presents STX-478 Data For Solid Tumors At ESMO Congress 2024
    Scorpion Presents STX-478 Data For Solid Tumors At ESMO Congress 2024

    15 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240915231694/en

    BUSINESSWIRE
    15 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search